Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer.

Hiroyuki OkuyamaYoshinori KagawaToshiki MasuishiSaori MishimaHiromichi ShirasuKoji AndoSatoshi YukiKei MuroTakayuki YoshinoKentaro YamazakiEiji OkiYoshito KomatsuAkihito Tsuji

Published in: International journal of clinical oncology (2021)

The incidence of ramucirumab-induced IRRs without antihistamine premedication is low. Not using antihistamine premedication can decrease medical costs. These findings warrant further investigation in large-scale cohorts to clarify the incidence and severity of ramucirumab-induced IRRs and further clarify the proper use of ramucirumab.

Keyphrases

high glucose
diabetic rats
risk factors
healthcare
drug induced
low dose
endothelial cells
metastatic colorectal cancer